Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT06232044. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Multiple myeloma is a cancer that affects white blood cells called plasma cells, which are made in the bone marrow and are part of the immune system. Multiple myeloma cells have a protein on their surface called B-cell maturation antigen (BCMA) that allows the cancer cells to survive and grow. Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Belantamab mafodotin has been designed to attach to the BCMA protein, which may cause the myeloma cell to become damaged and die. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Iberdomide plus belantamab mafodotin may help slow or stop the growth of cancer in patients with multiple myeloma.
Study identification
- NCT ID
- NCT06232044
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 88 participants
Conditions and interventions
Interventions
- Iberdomide Drug
- Belantamab Mafodotin Biological
- Dexamethasone Drug
- Echocardiography Procedure
- Computed Tomography Procedure
- Magnetic Resonance Imaging Procedure
- Positron Emission Tomography Procedure
- Bone Marrow Biopsy Procedure
- Bone Marrow Aspiration Procedure
- Biospecimen Collection Procedure
Drug · Biological · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 22, 2025
- Primary completion
- Apr 30, 2028
- Completion
- Jul 31, 2030
- Last update posted
- Aug 4, 2026
2025 – 2030
United States locations
- U.S. sites
- 43
- U.S. states
- 11
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mary Greeley Medical Center | Ames | Iowa | 50010 | Recruiting |
| McFarland Clinic - Ames | Ames | Iowa | 50010 | Recruiting |
| McFarland Clinic - Boone | Boone | Iowa | 50036 | Suspended |
| McFarland Clinic - Trinity Cancer Center | Fort Dodge | Iowa | 50501 | Recruiting |
| McFarland Clinic - Jefferson | Jefferson | Iowa | 50129 | Suspended |
| McFarland Clinic - Marshalltown | Marshalltown | Iowa | 50158 | Recruiting |
| Our Lady of the Lake Physician Group | Baton Rouge | Louisiana | 70808 | Recruiting |
| Tufts Medical Center | Boston | Massachusetts | 02111 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud | Minnesota | 56303 | Recruiting |
| Memorial Sloan Kettering Monmouth | Middletown | New Jersey | 07748 | Recruiting |
| Memorial Sloan Kettering Bergen | Montvale | New Jersey | 07645 | Recruiting |
| Memorial Sloan Kettering Commack | Commack | New York | 11725 | Recruiting |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| OhioHealth O'Bleness Hospital | Athens | Ohio | 45701 | Recruiting |
| Columbus Oncology and Hematology Associates Inc | Columbus | Ohio | 43214 | Recruiting |
| Riverside Methodist Hospital | Columbus | Ohio | 43214 | Recruiting |
| Grant Medical Center | Columbus | Ohio | 43215 | Recruiting |
| Doctors Hospital | Columbus | Ohio | 43228 | Recruiting |
| Delaware Health Center-Grady Cancer Center | Delaware | Ohio | 43015 | Recruiting |
| Grady Memorial Hospital | Delaware | Ohio | 43015 | Recruiting |
| Columbus Oncology and Hematology Associates | Dublin | Ohio | 43016 | Recruiting |
| Dublin Methodist Hospital | Dublin | Ohio | 43016 | Recruiting |
| OhioHealth Mansfield Hospital | Mansfield | Ohio | 44903 | Recruiting |
| OhioHealth Marion General Hospital | Marion | Ohio | 43302 | Recruiting |
| OhioHealth Pickerington Methodist Hospital | Pickerington | Ohio | 43147 | Recruiting |
| OhioHealth Westerville Medical Campus/Westerville Cancer Center | Westerville | Ohio | 43082 | Recruiting |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | Recruiting |
| Vanderbilt University/Ingram Cancer Center | Nashville | Tennessee | 37232 | Suspended |
| Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah | 84112 | Recruiting |
| Saint Vincent Hospital Cancer Center Green Bay | Green Bay | Wisconsin | 54301 | Recruiting |
| Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay | Wisconsin | 54303 | Recruiting |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Recruiting |
| ProHealth D N Greenwald Center | Mukwonago | Wisconsin | 53149 | Recruiting |
| ProHealth Oconomowoc Memorial Hospital | Oconomowoc | Wisconsin | 53066 | Recruiting |
| Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan | Wisconsin | 53081 | Recruiting |
| Sheboygan Physicians Group | Sheboygan | Wisconsin | 53081 | Recruiting |
| Marshfield Medical Center-River Region at Stevens Point | Stevens Point | Wisconsin | 54482 | Recruiting |
| Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay | Wisconsin | 54235-1495 | Recruiting |
| ProHealth Waukesha Memorial Hospital | Waukesha | Wisconsin | 53188 | Recruiting |
| UW Cancer Center at ProHealth Care | Waukesha | Wisconsin | 53188 | Recruiting |
| Marshfield Medical Center - Weston | Weston | Wisconsin | 54476 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06232044, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 4, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06232044 live on ClinicalTrials.gov.